Unusual Social Activity Around Illumina (ILMN) Today
Trade-Ideas LLC identified
(
) as an unusual social activity candidate. In addition to specific proprietary factors, Trade-Ideas identified Illumina as such a stock due to the following factors:
- ILMN has more that 20x the normal benchmarked social activity for this time of the day compared to its average of 3.35 mentions/day.
- ILMN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $213.9 million.
Identifying stocks with 'Unusual Social Activity' tends to be a valuable process for traders looking to capitalize on the 'talk of the town' stocks that are basking in far more attention from the StockTwits financial community than normal. Good press? Bad press? It ultimately doesn't matter if it's good or bad if you know how to trade around the sentiment. Certain hedge funds use such data for their proprietary algorithms and it is not uncommon to see shared social sentiment play itself out in a stock's price trend.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ILMN with the Ticky from Trade-Ideas. See the FREE profile for ILMN NOW at Trade-Ideas
More details on ILMN:
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. ILMN has a PE ratio of 49. Currently there are 6 analysts that rate Illumina a buy, no analysts rate it a sell, and 11 rate it a hold.
The average volume for Illumina has been 1.4 million shares per day over the past 30 days. Illumina has a market cap of $20.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.68 and a short float of 5.4% with 4.33 days to cover. Shares are down 26.9% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Illumina as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
Highlights from the ratings report include:
- Despite its growing revenue, the company underperformed as compared with the industry average of 12.0%. Since the same quarter one year prior, revenues slightly increased by 6.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The current debt-to-equity ratio, 0.51, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 3.63, which clearly demonstrates the ability to cover short-term cash needs.
- The gross profit margin for ILLUMINA INC is currently very high, coming in at 75.25%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 15.66% is above that of the industry average.
- ILLUMINA INC's earnings per share declined by 34.8% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ILLUMINA INC increased its bottom line by earning $3.10 versus $2.37 in the prior year. This year, the market expects an improvement in earnings ($3.38 versus $3.10).
- Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Life Sciences Tools & Services industry and the overall market on the basis of return on equity, ILLUMINA INC has underperformed in comparison with the industry average, but has exceeded that of the S&P 500.
- You can view the full Illumina Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.